Literature DB >> 1705894

Schistosome vaccines.

D W Taylor1.   

Abstract

Schistosomiasis control currently relies primarily on chemotherapy which is both expensive and temporary. There is an urgent need for an effective vaccine. Studies in animal models and man have demonstrated the existence of protective immunity. Antibody-dependent cell-mediated cytotoxicity mechanisms involving eosinophils and macrophages have been implemented in destruction of the parasites. Antigens expressed on the surface of the schistosomulum are among the targets of protective immune responses. Vaccines comprising recombinant antigens are now being tested in vivo for their capacity to evoke protective responses. Live oral vaccines based on attenuated Salmonella expressing schistosomular surface antigens are being developed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1705894     DOI: 10.1007/bf01945416

Source DB:  PubMed          Journal:  Experientia        ISSN: 0014-4754


  55 in total

1.  Characterization and cloning of Schistosoma mansoni immunogens recognized by protective antibodies.

Authors:  M Strand; J P Dalton; T D Tom
Journal:  Acta Trop Suppl       Date:  1987-06

2.  Identification by message selection of cDNA clones encoding antigens of Schistosoma mansoni.

Authors:  J S Cordingley; W J Haddow; V Nene; D W Taylor
Journal:  Mol Biochem Parasitol       Date:  1986-01       Impact factor: 1.759

3.  Regulation of antibody response in vitro. VI. Carrier-specific helper cells for IgG and IgE antibody response.

Authors:  T Kishimoto; K Ishizaka
Journal:  J Immunol       Date:  1973-09       Impact factor: 5.422

4.  Cloning of the gene encoding a 50 kilodalton potential surface antigen of Schistosoma mansoni.

Authors:  J C Havercroft; M C Huggins; V Nene; D W Dunne; B A Richardson; D W Taylor; A E Butterworth
Journal:  Mol Biochem Parasitol       Date:  1988-07       Impact factor: 1.759

5.  Schistosoma mansoni: detection by monoclonal antibody of a 22,000-dalton surface membrane antigen which may be blocked by host molecules on lung stage parasites.

Authors:  D A Harn; M Mitsuyama; E D Huguenel; J R David
Journal:  J Immunol       Date:  1985-09       Impact factor: 5.422

6.  Passive immunization of mice against Schistosoma mansoni with an IgM monoclonal antibody.

Authors:  M A Smith; J A Clegg; D Snary; A J Trejdosiewicz
Journal:  Parasitology       Date:  1982-02       Impact factor: 3.234

7.  Immunity after treatment of human schistosomiasis mansoni. I. Study design, pretreatment observations and the results of treatment.

Authors:  A E Butterworth; P R Dalton; D W Dunne; M Mugambi; J H Ouma; B A Richardson; T K Siongok; R F Sturrock
Journal:  Trans R Soc Trop Med Hyg       Date:  1984       Impact factor: 2.184

8.  Immunity after treatment of human schistosomiasis mansoni. II. Identification of resistant individuals, and analysis of their immune responses.

Authors:  A E Butterworth; M Capron; J S Cordingley; P R Dalton; D W Dunne; H C Kariuki; G Kimani; D Koech; M Mugambi; J H Ouma
Journal:  Trans R Soc Trop Med Hyg       Date:  1985       Impact factor: 2.184

9.  Immunity in human schistosomiasis mansoni: prevention by blocking antibodies of the expression of immunity in young children.

Authors:  A E Butterworth; R Bensted-Smith; A Capron; M Capron; P R Dalton; D W Dunne; J M Grzych; H C Kariuki; J Khalife; D Koech
Journal:  Parasitology       Date:  1987-04       Impact factor: 3.234

10.  Immunity in human schistosomiasis mansoni. Regulation of protective immune mechanisms by IgM blocking antibodies.

Authors:  J Khalife; M Capron; A Capron; J M Grzych; A E Butterworth; D W Dunne; J H Ouma
Journal:  J Exp Med       Date:  1986-11-01       Impact factor: 14.307

View more
  2 in total

Review 1.  Parasites and molecular biology.

Authors:  R J Terry
Journal:  Experientia       Date:  1991-02-15

2.  Cross-reactivity of Schistosoma mansoni cytosolic superoxide dismutase, a protective vaccine candidate, with host superoxide dismutase and identification of parasite-specific B epitopes.

Authors:  Claudia Carvalho-Queiroz; Rosemary Cook; Ching C Wang; Rodrigo Correa-Oliveira; Nicola A Bailey; Nejat K Egilmez; Edith Mathiowitz; Philip T LoVerde
Journal:  Infect Immun       Date:  2004-05       Impact factor: 3.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.